Cell therapy

CAR-T cell attacking cancer
#Cancer therapy #CAR-T #Cell therapy #Cytokine Release Syndrome (CRS) #Cytokines #Poolbeg Pharma

CRS prevention: Taking the sting from CAR-T’s tail

Advances in cancer therapy have produced powerful treatments that can greatly improve survival – but can also trigger fearsome side-effects. Notably, CAR-T cell therapies can cause cytokine release syndrome (CRS). Managing CRS is an area that is becoming increasingly important to Big Pharma, reports DDW’s Megan Thomas. CAR-T cell cancer… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell therapy #Haematology #Lymphoma #March Biosciences #Phase II trial

Phase II trial starts for CAR-T therapy in T-cell lymphoma

March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.   “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More

#Cancer Research #News

#Cancer research #Cell therapy #Drug development #Drug discovery #Oncology

New DDW Highlights podcast: 24 March 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week the DDW news round-up takes a look at developments in cancer research,… Read More

#News

#Cancer research #Cell therapy #Drug development #Drug discovery #Oncology

This week in drug discovery (17-21 March) 

News round-up for 17-21 March by DDW Senior Digital Content Editor Diana Spencer. This week the DDW news round-up takes a look at developments in cancer research, including AZ’s acquisition of EsoBiotec, positive trial results for an allogeneic T-cell therapy, and a new drug target for glioblastoma. Read More

#News

T cells attacking cancer
#Cell therapy #Haematology #Oncology #Orca Bio #Phase III trial

Allogeneic T-cell therapy doubles rate of survival free from GvHD

Biotechnology company Orca Bio has revealed positive results from the Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with haematological malignancies.  The trial included patients with acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute… Read More

#Cancer Research #News #Trending News

#AstraZeneca #Cell therapy #EsoBiotec #Mergers and acquisitions

AstraZeneca acquires in vivo cell therapy developer

EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca.  AstraZeneca will make an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones.  The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform is designed to empower… Read More

#Business & Investment #News

Bristol Myers Squibb offices
#Bristol Myers Squibb #CAR-T #Cell therapy #Mergers and acquisitions

BMS buys CAR-T company 2seventy bio

Bristol Myers Squibb (BMS) is to acquire cell therapy developer 2seventy bio for approximately $286 million.  Under the terms of the agreement, BMS will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction.   2seventy bio’s Board… Read More

#Business & Investment #News

Structure of the eye
#Cell therapy #FDA #Neurodegenerative disorders #Neurotech Pharmaceuticals #Ophthalmology

FDA approves first treatment for Macular Telangiectasia Type 2

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel).  MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients' quality of life.   Encelto utilises an encapsulated cell therapy… Read More

#News #Regulatory

Oslo stock exchange
#Cell therapy #Celluna #Natural killer cells #Oncology #Solid tumours

First cell therapy company lists on the Oslo Stock Exchange

Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange.  The share capital increases relating to the issuance of the Consideration Shares… Read More

#Business & Investment #News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Interview #Kite Pharma #Oncology

CAR-T cell therapy: Overcoming critical infrastructure challenges 

DDW’s Diana Spencer speaks to Dan Tovar, Senior Director, Head of Cell Therapy ACE Midsize Markets, Medical Affairs at Kite Pharma, about the current landscape for cell therapies and what can be done to improve patient access.  DS: Kite has pioneered cell therapy, with Yescarta (axicabtagene ciloleucel) as one of… Read More

#Business & Investment #Cancer Research #Exclusive Content

T cells attacking cancer
#Cell therapy #Immunotherapy #Oncology #Partnership

Swarm Oncology and Cellex partner to accelerate T cell therapies

Swarm Oncology and Cellex Cell Professionals have announced a new partnership with a particular focus on clinical and commercial supply of T cell therapies.  Despite advancements in oncology, more than 82% of patients with advanced metastatic cancer ultimately succumb to their disease.   Current immunotherapies provide only limited survival benefits due… Read More

#Business & Investment #News

CAR-T therapy
#CAR-T #Cell manufacturing #Cell therapy #Oncology

Bringing CAR-T cell production closer to patients

Dr Liping Yu, Vice President of Applications at Applied Cells, looks at barriers to access for CAR-T cell therapies. CAR-T cell therapies are increasingly being used to treat life-threatening conditions when other treatments have failed, particularly in oncology. Autologous CAR-T cancer therapies involve isolating T cells from a patient’s blood,… Read More

#Cancer Research #Exclusive Content

Cancer cell
#CAR-T #Cell therapy #Haematology #Interview #March Biosciences #Oncology

Pushing past the limitations of CAR-T therapies

DDW Editor Reece Armstrong speaks to Sarah Hein, CEO and Co-founder of March Biosciences, about the company’s recent fundraising efforts and its development of CAR-T therapies addressing challenging blood cancers. RA: What are the limitations of current standard-of-care therapies for blood cancers? SH: There are many treatment options for the… Read More

#Exclusive Content

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #FDA #Phase I trial

Allogeneic CAR-T therapy gets go-ahead for rheumatology trial

Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product.  The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including… Read More

#Cancer Research #News #Regulatory

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #FDA #Haematology #March Biosciences #Oncology

FDA Orphan Drug Designation for CD5 CAR-T cell therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).  MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL), and mantle cell… Read More

#News #Regulatory

#Autoimmune disease #CAR-T #Cell and gene therapy #Cell therapy

Expanding access to cell therapies for autoimmune conditions

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both… Read More

#Exclusive Content